Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines (Q30587338)

25 June 2017

Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines (English)

1 reference

25 June 2017

1 reference

2

Filip De Keyser

0 references

author name string

Fernanda Tavares Da Silva

1

1 reference

25 June 2017

Paul-Henri Lambert

3

1 reference

25 June 2017

William H Robinson

4

1 reference

25 June 2017

René Westhovens

5

1 reference

25 June 2017

Christian Sindic

6

1 reference

25 June 2017

language of work or name

English

0 references

publication date

4 February 2013

1 reference

25 June 2017

1 reference

25 June 2017

31

1 reference

25 June 2017

14

1 reference

25 June 2017

1870-1876

1 reference

Vaccination and autoimmune disease: what is the evidence?

25 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Could autoimmunity be induced by vaccination?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Evidence for coxsackievirus infection in primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Vaccinations in patients with immune-mediated inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Idiopathic thrombocytopenic purpura and MMR vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Hepatitis B vaccination and the risk of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Association of infectious mononucleosis with multiple sclerosis. A population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Definition of human autoimmunity--autoantibodies versus autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Exacerbation of pemphigus after influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Arthritis after hepatitis B vaccination. Report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Vaccination and autoimmune rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Epidemiology of autoimmune reactions induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Infection, vaccines and other environmental triggers of autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

"Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Transient appearance of the rheumatoid factor in connection with prophylactic vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Are anti-infectious vaccinations safe and effective in patients with autoimmunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Biologically plausible and evidence-based risk intervals in immunization safety research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Association between Campylobacter infection and Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Biomarkers for diagnosing and monitoring autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Range of antinuclear antibodies in "healthy" individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Diagnosis of autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

4. Autoimmunity, vasculitis, and autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Autoantibodies as predictors of disease: the clinical and experimental evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Interpretative comments on autoantibody tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Laboratory assessment in musculoskeletal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

From animal models to human genetics: research on the induction and pathogenicity of autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Proteomic biomarkers for autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Recent advances in diagnostic technologies for autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Advances and applications of multiplexed diagnostic technologies in autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Planning and core analyses for periodic aggregate safety data reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Measurement of patient outcome in arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.042

10.1016/J.VACCINE.2013.01.042

7 January 2021

Identifiers

DOI

1 reference

25 June 2017

1 reference